デフォルト表紙
市場調査レポート
商品コード
1589745

子宮内膜症治療薬市場:薬剤タイプ、治療タイプ、流通チャネル別-2025-2030年の世界予測

Endometriosis Treatment Market by Drug Type (GnRH Analogues, LNR-IUDS, NSAIDs), Treatment Type (Hormonal Therapy, Pain Management), Distribution Channel - Global Forecast 2025-2030


出版日
発行
360iResearch
ページ情報
英文 198 Pages
納期
即日から翌営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=152.30円
子宮内膜症治療薬市場:薬剤タイプ、治療タイプ、流通チャネル別-2025-2030年の世界予測
出版日: 2024年10月31日
発行: 360iResearch
ページ情報: 英文 198 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

子宮内膜症治療薬市場は、2023年に28億4,000万米ドルと評価され、2024年には30億5,000万米ドルに達すると予測され、CAGR 7.36%で成長し、2030年には46億8,000万米ドルに達すると予測されています。

子宮内膜症治療薬は、子宮内膜症(子宮外の子宮内膜組織の増殖を特徴とする慢性疾患)に関連する症状の管理と緩和を目的とした医療を幅広く網羅しています。効果的な治療の必要性は、子宮内膜症が女性の生殖の健康に重大な影響を及ぼし、慢性的な痛み、不妊、生活の質の低下をもたらすことに起因します。様々な用途には、個々の患者のニーズに合わせたホルモン療法、疼痛管理薬、外科的介入、ライフスタイルの変更が含まれます。最終用途には主に病院と外来手術センターが含まれ、さらに自己投与薬のための個人ケア環境も含まれます。市場成長の原動力は、認知度の向上、診断技術の進歩、世界の子宮内膜症の有病率の増加であり、効果的な治療ソリューションに対する需要の高まりが後押ししています。最新のビジネスチャンスは、非ホルモン薬や個別化薬などの新規治療薬の開発、低侵襲手術技術への関心の高まりにあります。患者教育プログラムに投資し、遠隔医療プラットフォームを活用することで、治療レジメンへのアクセシビリティとアドヒアランスを高めることもできます。しかし課題としては、高い治療費、ホルモン療法に伴う副作用、特定の地域における認知度の低さなどがあり、市場浸透の妨げとなっています。また、熟練した医療従事者の数が限られているなどの制限も、最適な治療の提供を妨げる要因となっています。技術革新としては、生物学的療法の研究、早期診断のための画像診断技術の強化、個別化治療計画における人工知能の統合に注力することが、成長の有望な道筋を示します。同市場は、既存製薬企業と、より低侵襲で効率的な治療オプションの導入に努める新規参入企業との激しい競合が特徴です。子宮内膜症患者の身体的・心理的ニーズに対応する患者中心の包括的ケアモデルを開発するためのヘルスケアプロバイダーや研究機関との提携は、企業にとって有益です。

主な市場の統計
基準年[2023] 28億4,000万米ドル
予測年[2024] 30億5,000万米ドル
予測年[2030] 46億8,000万米ドル
CAGR(%) 7.36%

市場力学:急速に進化する子宮内膜症治療薬市場の主要市場インサイトを公開

子宮内膜症治療薬市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的意思決定、新たなビジネスチャンスの獲得を行うことができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

  • 市場促進要因
    • 子宮内膜症の有病率の増加
    • 生殖年齢にある女性人口の増加
    • 世界の新薬の存在感の高まり
  • 市場抑制要因
    • 非侵襲的診断法の欠如
  • 市場機会
    • 新薬や治療手法開発のための研究活動の活発化
    • 子宮内膜症の新しい治療法を開発するためのナノテクノロジー利用の増加
  • 市場の課題
    • 子宮内システム(IUS)などの代替治療の存在

ポーターの5つの力:子宮内膜症治療薬市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析:子宮内膜症治療薬市場における外部からの影響の把握

外部マクロ環境要因は、子宮内膜症治療薬市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析子宮内膜症治療薬市場における競合情勢の把握

子宮内膜症治療薬市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的な意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス子宮内膜症治療薬市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、子宮内膜症治療薬市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によりベンダーを明確かつ的確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨子宮内膜症治療薬市場における成功への道筋を描く

子宮内膜症治療薬市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています:

1.市場の浸透度:現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度:新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化:最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報:競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション:将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています:

1.現在の市場規模と今後の成長予測は?

2.最高の投資機会を提供する製品、セグメント、地域はどこか?

3.市場を形成する主な技術動向と規制の影響とは?

4.主要ベンダーの市場シェアと競合ポジションは?

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か?

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

  • 市場力学
    • 促進要因
      • 子宮内膜症の罹患率の増加
      • 生殖年齢の女性人口の増加
      • 世界中で新薬の存在感が高まっている
    • 抑制要因
      • 非侵襲的診断の欠如
    • 機会
      • 新薬や治療法の開発に向けた調査活動の活発化
      • 子宮内膜症の新しい治療の開発にナノテクノロジーの利用が増加
    • 課題
      • 子宮内避妊システム(IUS)などの代替治療の存在
  • 市場セグメンテーション分析
  • ポーターのファイブフォース分析
  • PESTEL分析
    • 政治的
    • 経済
    • 社交
    • 技術的
    • 法律上
    • 環境

第6章 子宮内膜症治療薬市場薬の種類別

  • GnRHアナログ
  • LNR-IUDS
  • NSAIDs
  • 経口避妊薬
  • プロゲスチン

第7章 子宮内膜症治療薬市場治療の種類別

  • ホルモン療法
  • 疼痛管理

第8章 子宮内膜症治療薬市場:流通チャネル別

  • eコマース
  • 病院
  • 薬局
  • 小売薬局

第9章 南北アメリカの子宮内膜症治療薬市場

  • アルゼンチン
  • ブラジル
  • カナダ
  • メキシコ
  • 米国

第10章 アジア太平洋地域の子宮内膜症治療薬市場

  • オーストラリア
  • 中国
  • インド
  • インドネシア
  • 日本
  • マレーシア
  • フィリピン
  • シンガポール
  • 韓国
  • 台湾
  • タイ
  • ベトナム

第11章 欧州・中東・アフリカの子宮内膜症治療薬市場

  • デンマーク
  • エジプト
  • フィンランド
  • フランス
  • ドイツ
  • イスラエル
  • イタリア
  • オランダ
  • ナイジェリア
  • ノルウェー
  • ポーランド
  • カタール
  • ロシア
  • サウジアラビア
  • 南アフリカ
  • スペイン
  • スウェーデン
  • スイス
  • トルコ
  • アラブ首長国連邦
  • 英国

第12章 競合情勢

  • 市場シェア分析2023
  • FPNVポジショニングマトリックス, 2023
  • 競合シナリオ分析
  • 戦略分析と提言

企業一覧

  • Abbott Laboratories
  • AbbVie Inc.
  • Astellas Pharma Inc.
  • Bayer AG
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline PLC
  • Ipsen Pharma
  • Medtronic PLC
  • Merck & Co., Inc.
  • Myovant Sciences GmbH
  • Neurocrine Biosciences, Inc.
  • Orphagen Pharmaceuticals, Inc.
  • Sanofi S.A.
  • Stryker Corporation
  • Vital Health Endometriosis Center
図表

LIST OF FIGURES

  • FIGURE 1. ENDOMETRIOSIS TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 2. ENDOMETRIOSIS TREATMENT MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS ENDOMETRIOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS ENDOMETRIOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES ENDOMETRIOSIS TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES ENDOMETRIOSIS TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC ENDOMETRIOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC ENDOMETRIOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ENDOMETRIOSIS TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. ENDOMETRIOSIS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ENDOMETRIOSIS TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ENDOMETRIOSIS TREATMENT MARKET DYNAMICS
  • TABLE 7. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY GNRH ANALOGUES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY LNR-IUDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY NSAIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY ORAL CONTRACEPTIVES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY PROGESTINS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HORMONAL THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY E-COMMERCE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS ENDOMETRIOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. BRAZIL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. BRAZIL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 31. CANADA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. CANADA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. CANADA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 34. MEXICO ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. MEXICO ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. MEXICO ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. UNITED STATES ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 40. UNITED STATES ENDOMETRIOSIS TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. ASIA-PACIFIC ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 44. ASIA-PACIFIC ENDOMETRIOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 45. AUSTRALIA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. AUSTRALIA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. AUSTRALIA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 48. CHINA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. CHINA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. CHINA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 51. INDIA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. INDIA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. INDIA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 54. INDONESIA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. INDONESIA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. INDONESIA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 57. JAPAN ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. JAPAN ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. JAPAN ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 60. MALAYSIA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. MALAYSIA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. MALAYSIA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 63. PHILIPPINES ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. PHILIPPINES ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. PHILIPPINES ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 66. SINGAPORE ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. SINGAPORE ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. SINGAPORE ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 69. SOUTH KOREA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. SOUTH KOREA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. SOUTH KOREA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 72. TAIWAN ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. TAIWAN ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. TAIWAN ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 75. THAILAND ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. THAILAND ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. THAILAND ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 78. VIETNAM ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. VIETNAM ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. VIETNAM ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 85. DENMARK ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. DENMARK ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. DENMARK ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 88. EGYPT ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. EGYPT ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. EGYPT ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 91. FINLAND ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. FINLAND ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. FINLAND ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 94. FRANCE ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. FRANCE ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. FRANCE ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 97. GERMANY ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. GERMANY ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. GERMANY ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 100. ISRAEL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. ISRAEL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. ISRAEL ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 103. ITALY ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. ITALY ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. ITALY ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 106. NETHERLANDS ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. NETHERLANDS ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. NETHERLANDS ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 109. NIGERIA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. NIGERIA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. NIGERIA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 112. NORWAY ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. NORWAY ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. NORWAY ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 115. POLAND ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. POLAND ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. POLAND ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 118. QATAR ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. QATAR ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. QATAR ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 121. RUSSIA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. RUSSIA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. RUSSIA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 124. SAUDI ARABIA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. SAUDI ARABIA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. SAUDI ARABIA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH AFRICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. SOUTH AFRICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. SOUTH AFRICA ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 130. SPAIN ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. SPAIN ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. SPAIN ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 133. SWEDEN ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. SWEDEN ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. SWEDEN ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 136. SWITZERLAND ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. SWITZERLAND ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. SWITZERLAND ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 139. TURKEY ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. TURKEY ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. TURKEY ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED ARAB EMIRATES ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED ARAB EMIRATES ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED ARAB EMIRATES ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED KINGDOM ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. UNITED KINGDOM ENDOMETRIOSIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 147. UNITED KINGDOM ENDOMETRIOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 148. ENDOMETRIOSIS TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 149. ENDOMETRIOSIS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023
目次
Product Code: MRR-4348D129FA88

The Endometriosis Treatment Market was valued at USD 2.84 billion in 2023, expected to reach USD 3.05 billion in 2024, and is projected to grow at a CAGR of 7.36%, to USD 4.68 billion by 2030.

Endometriosis treatment encompasses a broad scope under medical care aimed at managing and alleviating the symptoms associated with endometriosis-a chronic condition characterized by the growth of endometrial tissue outside the uterus. The necessity for effective treatment stems from the significant impact of endometriosis on women's reproductive health, leading to chronic pain, infertility, and reduced quality of life. Various applications include hormonal therapies, pain management medications, surgical interventions, and lifestyle changes, tailored to individual patient needs. The end-use scope primarily involves hospitals and ambulatory surgical centers, complemented by personal care settings for self-administered medications. Market growth is driven by rising awareness, advancements in diagnostic technologies, and an increasing prevalence of endometriosis worldwide, encouraging greater demand for effective treatment solutions. The latest opportunities lie in the development of novel therapeutics, such as non-hormonal and personalized medicines, and the growing interest in minimally invasive surgical techniques. Investing in patient education programs and leveraging telehealth platforms can also enhance accessibility and adherence to treatment regimens. However, challenges include high treatment costs, side effects associated with hormonal therapies, and a lack of awareness in certain regions, impeding market penetration. Limitations like limited availability of skilled healthcare professionals can also hinder optimal treatment delivery. For innovation, focusing on research in biological therapies, enhancement of imaging techniques for early diagnosis, and integration of artificial intelligence in personalized treatment planning presents promising avenues for growth. The market is characterized by intense competition among established pharmaceutical companies and new entrants striving to introduce less invasive and more efficient treatment options. Businesses could benefit from partnerships with healthcare providers and research institutions to develop comprehensive, patient-centric care models that address both the physical and psychological needs of individuals affected by endometriosis.

KEY MARKET STATISTICS
Base Year [2023] USD 2.84 billion
Estimated Year [2024] USD 3.05 billion
Forecast Year [2030] USD 4.68 billion
CAGR (%) 7.36%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Endometriosis Treatment Market

The Endometriosis Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing prevalence rate of endometriosis
    • Increase in the female population within the reproductive age
    • Rising presence of novel drugs worldwide
  • Market Restraints
    • Lack of non-invasive diagnostics
  • Market Opportunities
    • Rise in research activities for development of new drugs and treatment methodologies
    • Rising use nanotechnology to develop new treatment for endometriosis
  • Market Challenges
    • Presence of alternative treatment such as Intrauterine Systems (IUS)

Porter's Five Forces: A Strategic Tool for Navigating the Endometriosis Treatment Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Endometriosis Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Endometriosis Treatment Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Endometriosis Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Endometriosis Treatment Market

A detailed market share analysis in the Endometriosis Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Endometriosis Treatment Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Endometriosis Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Endometriosis Treatment Market

A strategic analysis of the Endometriosis Treatment Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Endometriosis Treatment Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., Astellas Pharma Inc., Bayer AG, F. Hoffmann-La Roche Ltd, GlaxoSmithKline PLC, Ipsen Pharma, Medtronic PLC, Merck & Co., Inc., Myovant Sciences GmbH, Neurocrine Biosciences, Inc., Orphagen Pharmaceuticals, Inc., Sanofi S.A., Stryker Corporation, and Vital Health Endometriosis Center.

Market Segmentation & Coverage

This research report categorizes the Endometriosis Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug Type, market is studied across GnRH Analogues, LNR-IUDS, NSAIDs, Oral Contraceptives, and Progestins.
  • Based on Treatment Type, market is studied across Hormonal Therapy and Pain Management.
  • Based on Distribution Channel, market is studied across E-Commerce, Hospital, Pharmacies, and Retail Pharmacies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing prevalence rate of endometriosis
      • 5.1.1.2. Increase in the female population within the reproductive age
      • 5.1.1.3. Rising presence of novel drugs worldwide
    • 5.1.2. Restraints
      • 5.1.2.1. Lack of non-invasive diagnostics
    • 5.1.3. Opportunities
      • 5.1.3.1. Rise in research activities for development of new drugs and treatment methodologies
      • 5.1.3.2. Rising use nanotechnology to develop new treatment for endometriosis
    • 5.1.4. Challenges
      • 5.1.4.1. Presence of alternative treatment such as Intrauterine Systems (IUS)
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Endometriosis Treatment Market, by Drug Type

  • 6.1. Introduction
  • 6.2. GnRH Analogues
  • 6.3. LNR-IUDS
  • 6.4. NSAIDs
  • 6.5. Oral Contraceptives
  • 6.6. Progestins

7. Endometriosis Treatment Market, by Treatment Type

  • 7.1. Introduction
  • 7.2. Hormonal Therapy
  • 7.3. Pain Management

8. Endometriosis Treatment Market, by Distribution Channel

  • 8.1. Introduction
  • 8.2. E-Commerce
  • 8.3. Hospital
  • 8.4. Pharmacies
  • 8.5. Retail Pharmacies

9. Americas Endometriosis Treatment Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Endometriosis Treatment Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Endometriosis Treatment Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. AbbVie Inc.
  • 3. Astellas Pharma Inc.
  • 4. Bayer AG
  • 5. F. Hoffmann-La Roche Ltd
  • 6. GlaxoSmithKline PLC
  • 7. Ipsen Pharma
  • 8. Medtronic PLC
  • 9. Merck & Co., Inc.
  • 10. Myovant Sciences GmbH
  • 11. Neurocrine Biosciences, Inc.
  • 12. Orphagen Pharmaceuticals, Inc.
  • 13. Sanofi S.A.
  • 14. Stryker Corporation
  • 15. Vital Health Endometriosis Center